A Phase 1 Study of the OX40 Agonist, BGB-A445, with or Without Tislelizumab, an Anti-Pd-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Tumor Regression
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined